Newsletter | October 6, 2026
FEATURED EDITORIAL
What FDA Inspectors Want From Your OOS File
By Aldo Xhango, GuideGxP
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
MOST POPULAR NEWS
•
QIAGEN Launches QIAmini To Automate Small-Batch Sample Preparation
Roche Launches Newborn Screening Test For Three Severe Genetic Conditions
Leica Biosystems Completes Acquisition Of StatLab
Cepheid Receives FDA Clearance For Xpert Respiratory Panel
EpiSign Launches METRIC 5-Base
Siemens Healthineers Launches Innovance D-Dimer 2.0 Assay
VB Spine Announces FDA Breakthrough Device Designation to ScolimiR-3D
Abbott Launches SimpleScreen CRC Blood Test
Caris Life Sciences Unveils The Next Evolution Of Liquid Biopsy With Enhanced Caris Assure
Countable Labs Sets A New Standard In Molecular Testing For Hematologic Malignancy Clinical Apps
NovoPath Comes To Market With The Next-Gen LIS That Has The Digital Pathology Workflow Built In
